Experts Highlight the Most Important Advances in HR+/HER2- Breast Cancer

Gain insights from leading experts on recent key practice-changing data including guidance on incorporating into practice to optimize the care of patients with HR+/HER2- early and metastatic breast cancer through an on-demand webcast and accompanying downloadable slides.

Share

Program Content

Events

Activities

Important Advances in HRpos HER2neg Breast Cancer
Experts Highlight the Most Important Advances in HR+/HER2- Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 25, 2025

Expires: October 24, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from Lilly and Stemline Therapeutics, Inc.

Lilly

Stemline Therapeutics, Inc.